104 results about "Minoxidil" patented technology

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a minoxidil solution for androgenetic alopecia, which takes a deep eutectic solvent as a core solvent system and contains 1.0-5.0% of minoxidil (active ingredient), 0.1-1.0% of preservative, 0.05-1% of stabilizer, a proper amount of sodium hydroxide (the pH value is adjusted to 4-9) and purified water. According to the minoxidil solution, the solubility of minoxidil is greatly improved through the deep eutectic solvent, the solubility of minoxidil reaches 779.85 mg / ml and is 389.9 times that of water, the deep eutectic solvent is used in the minoxidil solution, ethanol is not contained, the dosage of propylene glycol is as low as 3%, ethanol and high-dosage propylene glycol (20%-50%) in a traditional commercially available formula are prevented from being used, irritation to scalp is reduced, and the minoxidil solution is suitable for scalp care. The minoxidil solution is stable in content after 6 months under the condition of 40 DEG C / 60% RH, the in-vitro transdermal performance of the minoxidil solution is superior to that of a commercially available reference preparation of an ethanol and propylene glycol solvent system, and the minoxidil solution also has the advantages of high stability, remarkable hair growth ability and the like.

This disclosure provides a method for treating hair loss in a subject requiring treatment for hair loss, comprising topically administering an effective amount of cortexolone-17α-propionate and an effective amount of minoxidil to the subject. This disclosure further provides a topical pharmaceutical formulation comprising cortexolone-17α-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

This invention belongs to the fields of biomedicine and cosmetics, and discloses the application of holly glycoside in promoting hair growth and preventing hair loss. Holly glycoside promotes the transition of hair follicles from the telogen phase to the anagen phase (i.e., shortening the telogen phase and prolonging the anagen phase), and inhibits cyclophosphamide-induced apoptosis of hair follicle cells and DHT-induced miniaturization of hair follicles. In androgenetic alopecia, telogen effluvium, and chemical alopecia models, its hair growth-promoting effect is comparable to that of the positive control drug minoxidil. It has broad application prospects in pharmaceutical formulations, cosmetics, skincare products, and beauty products.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention discloses a hair-growing liniment and a preparation method thereof, and belongs to the technical field of pharmacy. The liniment comprises the following components in percentage by weight: 1-10% of minoxidil microspheres, 5-20% of a film-forming agent, 0.5-5% of a polypeptide compound, 5-30% of a liquid auxiliary material and the balance of deionized water. Wherein the minoxidil microspheres are of a three-layer structure composed of minoxidil in the inner layer, nano enzyme (cerium dioxide) in the middle layer and lactic acid-glycolic acid ester copolymer or chitosan in the outer layer, and controlled release and targeted delivery are achieved; the polypeptide compound is a compound of oldenlandia diffusa polypeptide and a copper curcumin derivative, and has the effect of synergistically repairing a hair follicle microenvironment. Tests prove that the liniment can remarkably prolong the release time of minoxidil, increase the retention volume of minoxidil in hair follicle parts and reduce absorption of the whole body, shows a hair growth promoting effect superior to that of a traditional preparation and a single-layer microsphere preparation in an animal model, and has good stability and use comfort.

This disclosure relates to a single pharmaceutical composition comprising a therapeutically effective or prophylactically effective amount of both minoxidil, or a similar antihypertensive vasodilator, and a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. This disclosure also relates to a pharmaceutical package comprising a pharmaceutical composition for oral administration of a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, and a pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. The disclosure further provides methods of treating or preventing hair loss in a subject using the disclosed compositions and packages.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The present disclosure provides a method of treating hair loss in a subject in need thereof, comprising topically administering to the subject an effective amount of cortexolone-17α-propionate and an effective amount of minoxidil. The present disclosure further provides a topical pharmaceutical formulation comprising cortexolone-17α-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

The present application relates to a kind of minoxidil external solution and its preparation process, including 3 portions minoxidil, 30-40 portions ethanol, 5-7 portions propylene glycol, 0.005-0.02 portions antioxidant, 0.1-0.3 portions chelating agent, 58-60 portions purified water.The present application adds suitable antioxidant and chelating agent, so that minoxidil external solution reduces the generation of oxidation reaction in storage and use process, effectively prevents the problem of long-term storage discoloration, and the stability of the minoxidil external solution is high.By improving the formula and filtering process, microporous filter membrane is used for the original liquid, and repeated filtration is at least 2 times, and the filtration pressure and filtration temperature are repeatedly changed every minute;Finally, the amount of minoxidil adsorbed and retained by microporous filter membrane during filtration is very low (adsorption rate is less than 0.5%), which is significantly lower than the existing level, the stability of the effective component of product is high, and the qualified rate of product is significantly improved.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The invention provides N-acylamino acid and application thereof, and relates to a novel compound and application thereof, the novel compound N-farnesyl acetyl amino acid or geranyl amino acid and application thereof, and the compound has remarkable 5 alpha reductase inhibitory activity, can promote hair growth and has low side effects. The N-(farnesyl acetyl or geranyl) amino acid provided by the invention has significant 5 alpha reductase inhibitory activity, and can effectively reduce DHT level, thereby promoting hair growth. Compared with the existing hair growth drug minoxidil, the compound provided by the invention has higher hair growth efficiency and lower side effects, and is expected to become a candidate drug of a new generation of hair growth drugs. The preparation method is simple, efficient and suitable for industrial production.

For minoxidil in a minoxidil-containing formulation to be efficiently absorbed through the scalp, it is important that the formulation blends well with and spreads across the surface of the scalp. In other words, the object of the present invention is to provide a minoxidil-containing topical pharmaceutical composition that blends well with the skin. [Solution] (a) 5-15 w / v% minoxidil, (b) at least one selected from the group consisting of cetylpyridinium and its salts, and benzethonium and its salts, and (c) 8-30 w / v% water, (d) lower alcohol, and (e) 10-30 w / v% polyhydric alcohol. A topical pharmaceutical composition characterized in that the polyhydric alcohol is at least one selected from the group consisting of 1,3-butylene glycol, dipropylene glycol, propylene glycol, glycerin, and polyethylene glycol.

A pharmaceutical formulation for treating alopecia, a preparation method therefor and the use thereof are provided. Specifically, a formulation or composition for treating alopecia contains the following active components on the basis of the mass percentage (w / w) or mass / volume percentage (w / v): (a) 5% of minoxidil; and (b) 0.07-0.095% of finasteride. The formulation or the composition is a foaming agent or a liniment. When the formulation is a foaming agent, the total mass in the mass percentage does not contain the mass of a propellant.

The invention provides a sustained-release medicinal preparation for preventing and treating alopecia as well as a preparation method and application of the sustained-release medicinal preparation, and belongs to the technical field of biological medicines. The medicine for preventing and treating alopecia is prepared from the following components: 1 to 2.5 mg of finasteride, 4 to 6 mg of minoxidil, 20 to 60 mg of spirolactone, 10 to 20 mg of isotretinoin, 3 to 8 mg of vitamin B5, 50 to 100 mg of zinc and 5 to 10 mg of vitamin b6. The components cooperate with one another to activate hair follicle stem cells, increase the number of hair follicles and synergistically enhance the ability of promoting hair regeneration, so that a better alopecia prevention and treatment effect is achieved; the pharmaceutical preparation prepared by selecting a specific filler, an adhesive, a sustained-release framework material and a lubricant in a reasonable proportioning range has good sustained-release performance, the dosage and frequency of the medicine are greatly reduced, and the side effect is far lower than that of an oral medicine in a common dosage form.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

Compositions containing minoxidil are provided. The composition contains (A) minoxidil and (B) a polycyclic terpene.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

This invention discloses an illite@γ-CD-MOF composite drug-loaded material, its preparation method, and its applications. The illite@γ-CD-MOF composite drug-loaded material is obtained by reacting illite, γ-CD-MOF, and minoxidil in an ethanol solution. The illite@γ-CD-MOF composite drug-loaded material provided by this invention not only has a good appearance but also high drug loading capacity and high potassium ion release rate. When the illite@γ-CD-MOF composite drug-loaded material is blended with PVA to form an illite@γ-CD-MOF composite drug-loaded material / PVA composite drug-loaded film, its use not only reduces scalp damage from direct application but also allows for safer and more effective drug delivery, with a high drug release rate, demonstrating significant application value.

The invention discloses an application of minoxidil in preparation of a medicine for treating myelodysplastic syndrome, an effect of the medicine in hematopoietic development processes of zebra fish and mice and an application of the medicine in treatment of the myelodysplastic syndrome (MDS). In a zebra fish model organism, the influence of minoxidil on the hematopoietic development process is determined, and the minoxidil regulates the hematopoietic stem progenitor cell development by influencing the expression of wnt4. The medicine prepared from minoxidil and used for treating myelodysplastic syndrome (MDS) can play a role in treating myelodysplastic syndrome by regulating hematopoietic stem progenitor cell development.

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

A pharmaceutical package for treating / preventing hair loss in a subject comprising a first pharmaceutical composition for oral administration of a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, a second pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of a 5-α reductase inhibitor and a third pharmaceutical composition for oral administration, or either / and the first or second pharmaceutical composition, comprising a therapeutically effective or prophylactically effective amount of one or more hair growth / hair loss prevention supplements. A single pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, a therapeutically effective or prophylactically effective amount of a 5-α reductase inhibitor and a therapeutically effective or prophylactically effective amount of one or more hair growth / hair loss prevention supplements. Methods of treating or preventing hair loss using the disclosed compositions and packages

The present invention discloses a method for promoting hair growth at the eyebrow, eyelid, hairline, hairline, and hairline, wherein the method comprises applying to the eyebrow and eyelid separately from 0.0001% to 8% w / w or a composition of 0.0001% to 8% w / w of bemaprost and 0.0001% to 10% w / w of minoxidil.

The invention relates to the technical field of pharmaceutical preparations. The invention provides a sustained-release capsule containing minoxidil and dutasteride and a preparation method of the sustained-release capsule, the sustained-release capsule is composed of a capsule shell and content, and the content comprises minoxidil, dutasteride, spirolactone, isovitamin A, a traditional Chinese medicine composition, a sustained-release material, a filling material, an adhesive, a lubricant, a traditional Chinese medicine solubilizing dispersant and a stabilizer. According to the sustained-release capsule, through the synergistic effect of chemical components and traditional Chinese medicine components, the medicine components are better and more stable, the duration time of the medicine effect is prolonged, and the side effects of hirsutism, edema and the like caused by minoxidil and the side effects of transaminase abnormality and the like caused by dutasteride are reduced; meanwhile, by means of the liver protecting and blood nourishing effects of the traditional Chinese medicine components, the liver metabolism pressure is better reduced, and the long-term medication safety is improved; the hair regeneration capability is enhanced, and a better alopecia prevention and treatment effect is achieved.

A method for promoting hair regrowth in a subject includes performing microneedling on a region of a scalp of the subject to a depth of 0.5 millimeters (mm) to 1.5 mm, applying at least one therapeutic agent to the microneedled region, wherein the at least one therapeutic agent comprises Minoxidil, Finasteride, and Dutasteride, and implanting non-permanent pigment particles into a superficial dermis of the microneedled region, the microneedling, the applying, and the implanting together synergistically stimulating hair follicle activity.

In an aerosol preparation containing minoxidil and hyaluronic acid or a salt thereof, the analysis over time... To provide an aerosol agent that suppresses discharge. [Solution] (a) minoxidil, (b) hyaluronic acid or a salt thereof, and (c) polyhydric alcohols (d) an aerosol agent comprising a stock solution and a propellant.